NASDAQ: MDGLMadrigal Pharmaceuticals Inc Stock
$222.26-6.08 (-2.66%)
Updated Apr 18, 2024
MDGL Price
$222.26
Fair Value Price
-$0.92
Market Cap
$4.42B
52 Week Low
$119.76
52 Week High
$322.67
P/E
-11.12x
P/B
10.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$373.63M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.58
Operating Cash Flow
-$324M
Beta
0.8
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MDGL Overview
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MDGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDGL ($222.26) is overvalued by 24,139.5% relative to our estimate of its Fair Value price of -$0.92 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MDGL ($222.26) is not significantly undervalued (24,139.5%) relative to our estimate of its Fair Value price of -$0.92 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MDGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MDGL due diligence checks available for Premium users.
Be the first to know about important MDGL news, forecast changes, insider trades & much more!
MDGL News
Valuation
MDGL fair value
Fair Value of MDGL stock based on Discounted Cash Flow (DCF)
Price
$222.26
Fair Value
-$0.92
Undervalued by
24,139.50%
MDGL ($222.26) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MDGL ($222.26) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MDGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MDGL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.12x
Industry
15.68x
Market
41.33x
MDGL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.91x
Industry
5.76x
MDGL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MDGL's financial health
Profit margin
Revenue
$0.0
Net Income
-$112.2M
Profit Margin
0%
MDGL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$640.5M
Liabilities
$235.2M
Debt to equity
0.58
MDGL's short-term assets ($637.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDGL's short-term assets ($637.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDGL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MDGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$79.9M
Investing
-$362.1M
Financing
$479.9M
MDGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDGL vs Biotech Stocks
Madrigal Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.